Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”

To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
- Published in Press Releases
The FDA Vs Stem Cell Treatments In The US
Introduction
Stem cell therapy has become a popular type of treatment for a number of conditions, including the regeneration of injured tissue or diseased cells in the human body. This therapy is classified as regenerative medicine. Several advancements have already been made in this medical field, and many have experienced positive results when they underwent stem cell therapy to assist in the treatment of degenerative conditions.
Benefits and Concerns of Stem Cell Therapy
While stem cell therapy has been proven to provide an effective protocol in the recovery of stroke, neurological issues, and even to assist in repairing the damage caused by a heart attack, recent reports have caused many to view these treatments negatively. This is due to warnings that were recently issued by the FDA. Even though some have experienced side effects due to the use of stem cell therapy, it is important to note that there are facilities within the US that can provide professional services that help to minimize the risk of these adverse events.
The FDA’s Stance on Stem Cell Therapy in the United States
The Food and Drug Administration of the United States is involved in analyzing and approving medications and medical procedures that may be offered to patients in the country. To date, the FDA has shown some interest in stem cell therapy, providing approval for several clinical trials that looked at how effective this treatment is in providing a regenerating effect on the impact that certain conditions have on the human body. However, only one particular treatment involving stem cell therapy has been officially approved by the FDA.
Recent FDA Actions and Their Impact
Within the last few months, several concerning publications have been made by the FDA regarding stem cell therapies, reducing the hope that some patients might have gained. On June 25, 2019, the FDA published a statement describing a permanent injunction against many stem cell clinics in the country. The FDA stated that the action taken from their side is to assist in providing a layer of protection for patients, due to the risks involved with undergoing treatments that utilize products that have not gone through any type of approval process.
The Case Against US Stem Cell Clinic LLC
The specific company targeted in this statement and by the actions taken by the FDA is known as US Stem Cell Clinic LLC. The court ruled in favor of the FDA and US government earlier in June, finding the defendants, being US Stem Cell Clinic LLC, guilty of the claims made against them. An earlier publication also confirmed that the Federal court ruled the misbranding of the stem cell products released by the US Stem Cell Clinics company as a violation of laws implemented to protect the people of the country.
Implications of FDA Regulations on Stem Cell Treatments
News publications have announced that the regulations and guidelines set out by the FDA might cause a significant decline in the availability of stem cell treatments to patients in the United States. The companies targeted by these particular actions are primarily those marketing products that have not gone through approval phases – and these products have been found to put the patient’s health at risk.

The Role of Stem Cell Therapy in Disease Treatment
While some companies have been found guilty of using unapproved and misleading products on patients, promoted as stem cell therapy, it is important to consider the reality of the situation as well. Stem cell therapy, often referred to simply as cell therapy, has been proven to be a successful regime in the treatment of several conditions. Many of the conditions that have shown improvement with this therapy were previously considered difficult, or sometimes even impossible, to treat effectively.
Global Success of Stem Cell Therapy
By 2012, the Worldwide Network for Blood and Marrow Transplantation (WBMT) announced that a total of one million stem cell therapy procedures had been done throughout the world. This was a significant milestone, and these procedures have helped to save countless lives. The WBMT refers to a case of Marta, a girl from Madrid, who received stem cell therapy at a young age after being diagnosed with Leukemia. In 2002, Marta was able to overcome Leukemia, thanks to the cell therapy provided to her.
Expanding Applications of Stem Cell Therapy
While lymphoma and leukemia are the conditions where patients most frequently seek stem cell therapy, many other conditions are treated with this procedure today. The perfection of the therapy has led to treatments that can assist in reducing the effects of over 70 diseases that may otherwise have a significant impact on the human body.
GSCG Expands to Cancun, Meets the Demands of US Patients
The Global Stem Cells Group recently announced the opening of a new office in Cancun, Mexico. This decision was driven by the increasing demand for cell therapy procedures by patients in the United States and the lack of facilities able to provide these individuals with professional and quality services. Doctors specializing in regenerative medicine are also having a hard time fulfilling the needs of patients who wish to consider cell therapy as a potential treatment option.
GSCG’s Facilities in Cancun
This is not the only local office that GSCG operates in Cancun, as the company now has two facilities within this location. These offices include a stem cells laboratory and a general medical facility. Over the years, GSCG has become an established name in the stem cell field, providing thousands of doctors the opportunity to offer cell therapy as a treatment option for patients with degenerative diseases. This therapy may assist in the regeneration of damaged and diseased tissues in the patient’s body.
Ensuring Quality and Safety at GSCG
Even though a previous office had established a presence for GSCG in Cancun, the company announced that the opening of the new office means they have now officially created a permanent presence for the brand in the area. GSCG’s new facility in Cancun is equipped with the latest advancements in the field and provides quality services that ensure patients have a trusted medical facility where they can undergo cell therapy as part of a regenerative medicine treatment plan.
Support for US Doctors in Regenerative Medicine
Doctors in the field of regenerative medicine within the United States can now turn to this facility to offer their patients an additional treatment option, apart from the standard pharmaceutical protocols. The stem cell laboratory can assist in analyzing patient data and finding a matching donor for those in need of stem cell treatment. GSCG’s facility can help with the culturing of expanded autonomous cells and other cell types utilized in stem cell therapy. A detailed approach is taken, considering the age of the donor, which provides an overview of the autonomous stem cell age. The patient being treated is also closely considered, as there are different methods of introducing these stem cells to the body for enhanced efficacy.
Advanced Treatment Methods at GSCG
A more aggressive method is often needed for patients with conditions such as autism, Alzheimer’s disease, and kidney-related conditions. Other conditions treated include pulmonary diseases and Parkinson’s disease. In cases of stroke, the vascular arteries, along with the carotid artery, are targeted with the therapy for a more effective approach to assisting with the regeneration of damaged structures in the patient’s brain. This ultimately leads to a significant improvement in the delivery of stem cells to the patient’s body, enhancing the overall efficacy of the treatment.
Comprehensive Patient Care at GSCG
When procedures are provided to the patient through the GSCG, an appropriate ICU unit is made available to ensure the patient is provided with adequate care during the operation and recovery. The utilization of recent technological advancements at GSCG laboratories can also assist in providing a more economical approach to cell therapy. Allogenic stem cell procedures can be addressed using techniques that reduce the costs involved, making these treatments available to patients at a lower price.
Advanced Cultivation Techniques at GSCG
The utilization of autologous stem cell transplantation offers an opportunity for patients to undergo stem cell therapy when a sibling does not provide an ideal match. Cells can be cultivated from the bone marrow and treated with specific drugs to yield targeted results. In the case of malignant cells, bone marrow can be treated with monoclonal antibodies or cytotoxic drugs to target such cells when transplanted back into the patient. Appropriate storage solutions are also considered to assist with the cultivation process and reduce the risk of enzymatic treatment leading to the differentiation of cells into other types. The culture condition becomes crucial for the expansion of stem cells, utilizing mediums and techniques that ensure successful cultivation and expansion.
The GSCG’s Role in the New FDA Warnings
The FDA’s recent warnings and actions against certain stem cell therapy products have caused a limitation in access to these treatments. With the seizure of services provided by companies affected by the FDA’s actions, patients may not be sure where to turn. This issue also affects many doctors in regenerative treatments and medicine, as they need to ensure that the facilities they use for patients offer safe procedures.
GSCG’s Trusted Services
This is where the GSCG comes into the picture. With an established presence in Mexico, doctors now have access to a facility with a history of providing quality stem cell therapy services to patients with qualifying diseases. The company is trusted and has performed stem cell therapy procedures that have led to successful results.
Hope for Patients Through GSCG
These treatments may help repair neurological problems caused by disorders like Parkinson’s disease, stroke, or spinal cord injuries. They may also offer new hope to people with diabetes, heart disease, and those who have suffered cardiovascular damage due to a heart attack.
Conclusion
Even though recent FDA publications have raised concerns regarding stem cell therapy, many patients are still interested in undergoing these treatment procedures. A significant number of studies have provided evidence on the efficacy of treating tissue damage caused by various conditions through stem cell therapy. Patients interested in undergoing stem cell treatment are now advised to turn their interest to Stem Cells Centers in Cancun and related regions, where highly specialized and experienced doctors can provide professional service.
- Published in Corporate News / Blog
ISSCA Set to Welcome 13 Speakers at Upcoming Symposium in Miami
The regenerative medicine symposium will be held on the University of Miami campus on October 24, 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA) has announced its lineup of speakers for its upcoming Regenerative Medicine Symposium. The symposium will be held on the University of Miami campus in the Donna E. Shalala Student Center on October 24, 2019 and features an impressive lineup of global authorities in regenerative medicine.
ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. This year’s symposium hosted on the University of Miami campus will feature industry experts from seven countries, including Spain, Argentina, Bolivia, Colombia, Ecuador, Mexico, and the US. Some notable speakers include the following:
- Dra. Silvina Pastrana from Argentina, who serves as the Medical Director of the Stem Cells Center Buenos Aires. Dra. Pastrana will discuss her experiences in treating patients who suffer from osteoarthritis conditions.
- Dr. Pedro Sanchez hails from Colombia and is a highly regarded regenerative medicine and orthopedic specialist. He currently practices in Bogota where he offers stem cells treatments for people who suffer from orthopedic conditions.
- Dr. Miguel Guillermo Garbe of Spain serves as the president of the country’s Regenerative Medicine Association. He currently leads a seminal investigation on how to increase cardiological function in patients who have suffered from strokes.
- Dr. Roberto Blum from Ecuador has worked in the stem cells field for over 10 years and will share his industry experience with attendees.
- Dr. Victor Pereyra, an Argentinian neurosurgeon, will lecture on how ozone therapy and stem cells could help patients suffering from spinal injuries.
“The symposium will provide an informative day where physicians can learn from global leaders in the stem cells industry with the hopes of bringing new knowledge and treatment options back to their practices for their patients suffering from degenerative diseases.”
To learn more about the ISSCA and its Miami symposium, visit
http://www.stemcellsgroup.com/.
.
- Published in Press Releases
GSCG Meets Demands of Patients Seeking Stem Cells Treatment with New Facilities
The group’s new permanent office in Cancun will help streamline the patient experience by providing holistic support throughout the treatment process.
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) today announced that it will be opening a permanent office in Cancun, Mexico. The decision to expand its corporate presence into Cancun was based on the rising demand for patients seeking stem cells treatments at the group’s facilities already established in Cancun. The GSCG maintains two regenerative medicine operations in Cancun, which include medical facilities and a stem cells laboratory.
GSCG’s Cancun facilities provide state-of-the art options for patients seeking stem cells treatments that are currently not available in the US. While these protocols and products are currently unavailable within the US’s borders due to regulations, the Cancun center has still adopted the FDA’s frameworks for safe and effective regenerative medicine products and therapies. Guided by these protocols, physicians at the center deliver safe and effective stem cells therapies and products that can help patients suffering from degenerative diseases recover more quickly than with traditional treatment protocols.
With the establishment of a permanent office presence in Cancun, the GSCG seeks to provide a seamless holistic experience for patients seeking treatment at its facilities. With its office located near its medical center and laboratory, the GSCG team can more closely monitor the treatment process from the time the patient arrives at the Cancun airport to the time their treatment is complete and they return to the US.
“The Global Stem Cells Group is pleased to establish a permanent presence in Cancun with the opening of this new office location,” said Benito Novas, CEO of the Global Stem Cells Group. “By expanding our presence, we will be able to open up additional treatment opportunities for physicians in the US who may be limited by FDA regulations in ensuring their patients receive the critical stem cells therapies they need. US patients looking for relief from regenerative diseases are welcome at our Cancun center and will appreciate our state-of-the art facilities and top-notch care.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
.
- Published in Press Releases
How To Effectively Treat Amyotrophic Lateral Sclerosis (ALS)
What is ALS?
Although a rare neurologic condition, Amyotrophic Lateral Sclerosis (ALS) is the most common type of Motor Neuron Disease (MND), a condition that affects the voluntary muscles. This is a progressive disorder that leads to muscle weakness and depletion due to nerve dysfunction.
ALS is also called Lou Gehrig’s disease, named after the football player who had this condition. The literal meaning of Amyotrophic is ‘no muscle nourishment,’ which becomes the cause of muscle atrophy. ‘Lateral’ refers to the group of nerves in the spinal cord that sends signals to the muscles. It is these nerves that degenerate, leading to sclerosis in this region. In later stages, this affects the nerves that control breathing and hence can be fatal.
Initial Symptoms of ALS
The initial symptoms of ALS include stiffness and muscle weakness, which gradually involve all the muscles under voluntary control. The affected regions and progressive pattern vary from one person to another. Some have difficulty holding a pen or a cup, while others find difficulty speaking, chewing, or even talking. Thus, ALS is an ailment that affects daily life and makes simple tasks painful and troublesome.
ALS Statistics
According to the Center for Disease Control and Prevention (CDC), 14,500 to 15,000 people had ALS in the United States in 2016, with approximately 5000 people having a confirmed diagnosis for the condition annually. Although the average survival rate is three to five years, patients can live for ten years or more.
Types of ALS
Sporadic ALS
This is the most common type and affects 95% of sufferers. This type occurs without a clear cause.
Familial ALS (FALS)
This type occurs in 5-10% of sufferers. This type of ALS is genetic and runs in families. This occurs due to abnormal changes to a gene that is then passed in generations.

Symptoms of ALS
What are the symptoms of ALS?
Early signs and symptoms might be unnoticeable and become perceptible after some time. Most clinical signs are evident of upper motor neuron and lower motor neuron lesions. The limb onset ALS (70%) involves initial symptoms in the limbs, while the bulbar onset ALS (25%) is characterized by speech and swallowing problems, followed by weakness in the limbs later. The remaining 5% of patients have respiratory involvement in the early period.
Most Common Symptoms Include:
- Muscle weakness in the limbs (distal or proximal)
- Asymmetric progressive muscle wasting
- Difficulty in motor activities like walking, talking, chewing
- Weakness in arms, legs, hands, and feet
- Muscle cramps and twitching
- Slurred speech
- Fatigue
- Emotional liability (episodes of uncontrolled laughing and crying)
- Difficulty in maintaining posture and gait
- Difficulty in breathing and swallowing
With the progression of the disease, symptoms may spread to all parts of the body. In some patients, frontotemporal dementia may occur, resulting in poor memory and decision-making abilities.
Causes of ALS
The exact cause of ALS has not been known by scientists to date. However, research is being carried out to understand what causes ALS. There are several different factors such as:
Genetic Changes
Studies have shown that 5 to 10% of cases of ALS are caused by genetic mutations. For example, changes to the gene that makes SOD1 protein causes damage to motor neurons.
Environmental Factors
No major association has been established between environmental factors like toxins, viruses, diet, or physical trauma and the risk of development of ALS. However, there is ongoing research on the subject. Studies have shown that some athletes are at a higher risk of acquiring ALS due to vigorous physical activity.
Chemical Disturbance
Glutamate is the neurotransmitter that is in control of signals to and from the brain. Accumulation of this neurotransmitter within the spaces surrounding the nerves damages them. Research has also shown mitochondrial structural and functional abnormalities, as well as defects in axonal structure and transport, could be the causative agents for ALS.
Diagnosis of ALS
When it comes to diagnosis, there are no specific tests that can provide a definitive diagnosis for ALS. However, doctors conduct a series of tests to rule other similar diseases. A full medical history check and a neurologic examination are undertaken at regular intervals to assess the progressive worsening of symptoms.
Diagnostic Tests Include:
- Electromyography (EMG): EMG records the electrical activity of the muscle fibers.
- Nerve Conduction Study (NCS): NCS assesses the electrical activity of the nerves and muscles.
- Magnetic Resonance Imaging (MRI): MRI rules out other possible conditions such as a tumor or cyst in the spinal cord, cervical spondylosis, or a hernia in the neck that could be causing the nerve compression.
Laboratory tests such as blood screening and urine tests can also be carried out so that other diseases can be eliminated.
Treatment Options & Management Strategies for ALS
ALS is managed through a multidisciplinary approach. Unfortunately, there is no definitive cure for the disease at this time. Management of ALS is done through symptomatic treatment to ease the condition of the patients and prevent unnecessary complications:
Support
Physicians, psychologists, speech therapists, nutritionists, and home care assistance all play a vital role in making life easier for patients with ALS.
Medication
Riluzole (Rilutek) and Edaravone (Radicava) are the drugs approved by the U.S Food and Drug Administration (FDA) for treating ALS. Riluzole is believed to reduce glutamate levels, thereby decreasing damage to the motor neurons. Edaravone acts as an antioxidant and is believed to expel free radicals and reduce oxidative stress in the motor neurons.
Lifestyle Habits
Physiotherapists can recommend exercise and physical activity like walking, swimming, and bicycling that may improve muscle strength and help elevate mood without overstressing the muscles.
Speech Therapy
Therapists can help patients with ALS to employ strategies to speak clearly. They may also recommend computerized aids such as speech synthesizers and eye-tracking technology to help people learn ways for responding by nonverbal means.
Diet
Nutritionists may formulate a diet plan for patients, which consists of food that is easy to swallow and provides enough nourishment and calories for the patients to maintain adequate energy levels and to prevent excessive weight loss.
Breathing Support
Patients with ALS may suffer from shortness of breath and difficulty breathing during physical activity or while lying down. If this is the case, doctors can recommend Non-Invasive Ventilation (NIV) that provides breathing support through the nose or mouth. NIV improves quality of life and increases the number of years of survival for patients.
Is Stem Cell Therapy an Option?
As previously mentioned, there is no curable treatment for ALS available. However, scientists are researching Stem Cell Therapy as the new favorable approach in the treatment of neurologic disorders. There is a rising interest in Stem Cell Therapy as a promising remedy for curing ALS. Mesenchymal stem cells are particularly believed to be the most suitable ones due to their availability, absence of ethical issues, and positive results in various experiments.
Research on Stem Cell Therapy
Studies and clinical trials have begun to apprehend the benefits of MSC transplantation. They demonstrate that MSCs lead to a partial recovery of motor neurons and a delay in disease progression. Also, there has been no evidence of a major adverse effect after MSC transplantation. When testing this newfound research on animals, the lifespan of the subjected animal has increased with MSC transplantation. These positive results have encouraged the administration of MSC in ALS patients.
However, despite the safe outcomes of MSC transplantation in humans, results show that there is only a partial improvement in ALS sufferers with only a few cases that showed a delay in disease progression. Hence, there is a need for further studies and trials on a higher number of human subjects for a better understanding of MSC effects so that more significant conclusions can be reached.
- Published in Corporate News / Blog
Benito Novas of Aesthetica Marketing Group Set as Keynote for Chilean Aesthetics Congress
The keynote will highlight trends in social media marketing for physicians working in aesthetics
MIAMI LAKES, Florida—Benito Novas, CEO of Aesthetica Marketing Group (AMG), has been selected to serve as the keynote speaker at the upcoming Congreso del la Sociedad Chilena de Medicina y Estética. AMG, which is sponsoring the Chilean congress, is an American company focused on providing doctors working in the aesthetics medical industry practical solutions for their marketing challenges. The congress will be held on August 22-24, 2019 at the Hotel InterContinental Santiago in Santiago, Chile.
The annual event is the group’s main event, attracting physicians in the aesthetics medical industry across Chile and beyond. Novas’ keynote lecture will highlight current trends and best practices in social media and how physicians working in the aesthetics industry can better leverage social media in increasing the success of their practices.
During the congress, AMG will also launch two new courses focused on the aesthetics market, Pellet Therapy Certification and an IV/Chelation course.
The Pellet Therapy Certification course will provide practitioners with comprehensive clinical knowledge of this therapy option—one that is gaining rapid traction and recognition globally. Facilitators will present scientific reviews, case studies, and procedural training during the workshop. Attendees will be provided an in-depth introduction to pellet therapy, supported by reviews of clinical evidence on the need for customized dosing, in addition to assessing pellet dosing protocols for male and female patients. Pellet sterility, equipment, and what to look for in a compounding pharmacy will also be discussed.
AMG’s IV/Chelation course has been redesigned and now includes the most recent practices and protocols in intravenous nutritional therapies, in addition to chelation therapy in regard to its uses in lead toxicity and other heavy metals. Lecturers will not only cover the fundamentals of IV therapy and expand on the use of vitamins, minerals, amino acids, and other unique parenteral compounds but also review various aspects of integrating IV therapy into practice, as well as implementation strategies. Faculty presenters additionally will discuss potential application of the therapy in cancer treatment protocols, thus giving attendees the unique opportunity to learn about the most cutting-edge uses of IV therapy as a treatment method. At the conclusion of the course, clinicians will have a thorough understanding of how to perform IV therapy in both theory and practice.
To learn more about the upcoming Congreso del la Sociedad Chilena de Medicina y Estética or to register, visit https://sochimce.cl/congreso/. To learn more about Aesthetica Marketing Group, visit https://esteticamarketing.com/.
.
- Published in Press Releases
Benito Novas to Serve as Keynote Speaker at Mexican Aesthetic Gynecology Congress
The Global Stem Cells CEO will give two additional lectures on marketing and future outlooks for the stem cells industry as well as lead a magistral class for attendees
MIAMI LAKES, Florida—Benito Novas has been invited as a keynote speaker at an upcoming medical congress hosted by the Mexican Board of Aesthetic Gynecology. The group’s fourth congress, the 4to Congreso Internacional de Ginecología Lasar y Funcional, will be held on September 25-28, 2019 at the Holiday Inn hotel in Boca del Rio in Veracruz, Mexico.
Novas, is the Vice President of Public Relations of the International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. In addition to his keynote speech, Novas will also lecture on two additional topics during the congress as well as lead a magistral class for conference attendees.
Benito Novas is a highly sought-after speaker in the world of stem cell advancements, having served as a successful business owner in the industry with his holding the Global Stem Cells Group. Thanks to Novas’ and his team’s efforts, access to regenerative medicine has expanded exponentially across the globe. Additionally, Novas is a well-regarded marketing professional who has created a successful marketing model for private medical organizations to expand and grow their industry recognition.
Congress attendees will have the opportunity to hear Novas’ talks on the current and future state of stem cells as well as the importance of digital marketing in the medical field. In his lecture on current and future outlooks for stem cells advancement, Novas will share information about current stem cells clinical trials and growing expectations in the industry as well as how FDA policies can influence markets not only in the US but also beyond.
In his lecture on digital marketing, Novas will address why doctors must utilize digital marketing strategies to grow a successful practice. He will look at current trends in how people meet each other and network in today’s increasingly digital world and how social medial plays a role in today’s networking. He will additionally provide strategic tips to attendees on how to capitalize on social media trends to grow practice influence. Some of the tools Novas will discuss include Google Ads and Facebook Ads, as well as what type of content to post to generate engagement with prospective customers and clients.
Novas will also conduct a magistral class following the congress for professionals interested in learning more about digital marketing. During the course, Novas will discuss how practitioners can implement the latest marketing techniques into their practices, including how to create a powerhouse digital marketing team by using platforms such as Fiverr, Upwork, and others.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
.
- Published in Press Releases
Stem Cells Group to Host Regenerative Medicine Symposium at the University of Miami
ISSCA will partner with SIISDET at the October 2019 event, which will share valuable information with physicians regarding recent breakthroughs in regenerative medicine
MIAMI LAKES, Florida—The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will co-host a symposium in October 2019 with the Sociedad Internacional en Investigación, Salud, Desarrollo Empresarial (SIISDET). The event will be held at the University of Miami on October 22-24, 2019 in the West Ballroom of the Shalala Student Complex.
The Miami symposium will feature educational sessions and product information and demonstrations aimed at doctors looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to share the latest information on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products.
Allogeneic compounds have gained growing popularity in regenerative medicine due to their increased safety and treatment efficacy. With this in mind, ISSCA representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their practices.
“We are pleased to be able to partner with SIISDET to be able to offer this exciting symposium at the University of Miami,” said Benito Novas, CEO of ISSCA. “We are continually seeking ways to bring the latest advances in regenerative medicine to physicians across the globe. Our Miami symposium will play a critical role in accomplishing this by helping physicians expand their knowledge bases and explore new treatment options in regenerative medicine.”
In addition to educational sessions, the Miami symposium will provide networking and social opportunities for those in attendance. Events on the agenda include an optional boat trip around Miami on the Miami River and a Columbian Day celebration offering live music and Colombian cuisine to symposium attendees.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
.
- Published in Press Releases
Benito Novas, Global Stem Cells Group CEO Announces Opening of New Stem Cell Center in Valencia, Spain
The new center will continue the Global Stem Cells Group’s mission to expand access to stem cell therapies and training to physicians across the globe.
MIAMI LAKES, Florida—A new Stem Cell Center is set to open its doors in Spain. Benito Novas, CEO of the Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced the opening of the group’s Valencia, Spain center. The new clinic will be the group’s third operation in Spain and the fourth in Europe.
The Global Stem Cells Group’s Valencia center joins the already existing centers in , which include locations in Bruselas, Madrid, and Barcelona. With the opening of the new center, the GSCG will boast 41 such locations across the globe.
Novas noted that the group has been focusing its efforts on opening its cutting-edge Stem Cell Centers in Europe, in part due to the group’s recognition that regenerative medicine is a fast-growing field across the continent.
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
“I am thrilled to lead the efforts at the Stem Cell Center in Valencia,” said Dra. Caicedo. “I am looking forward to utilizing cutting-edge therapy options based in stem cell science to help treat patients suffering from hair loss. Additionally, the opportunity is an exciting one given the Global Stem Cells Group’s excellent reputation and stature as the longest-standing and most respected stem cells network. I’m looking forward to learning from other physicians in the network across the globe and sharing my expertise with other practitioners in regenerative medicine.”
The GSCG will provide the Valencia center with the newest and most effective marketing tools in the field to help the franchise increase its performance in recruiting new patients.
Marketing support is one of the many benefits of joining the GSCG’s expanding global network of clinics. Being part of the group’s network gives physicians access to other experts within the its global network, add to their practice the newest regenerative medicine protocols, and have access to a proven marketing strategy developed by GSCG.
To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
.
- Published in Press Releases












